Sapna Syngal, MD, MPH
Associate Professor, Department of Medicine, Harvard Medical School
Associate Physician, Medicine, Brigham And Women's Hospital
Director, Gastroenterology DFCI/BWH Cancer Center, Medical Oncology, Dana-Farber Cancer Institute
Contact Info
Sapna Syngal
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 1124
Phone: 617-632-5022
Fax: 617-632-4088
sapna_syngal@dfci.harvard.edu
Administrative Specialist
Medical Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 1122
Phone: 617-632-6164
Fax: 617-394-2934
karyne_hoffman@dfci.harvard.edu
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 1124
Phone: 617-632-5022
Fax: 617-632-4088
sapna_syngal@dfci.harvard.edu
Assistant
Karyn HoffmanAdministrative Specialist
Medical Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 1122
Phone: 617-632-6164
Fax: 617-394-2934
karyne_hoffman@dfci.harvard.edu
DF/HCC Program Affiliation
Gastrointestinal MalignanciesCancer Genetics
Research Abstract
Dr. Syngal's research is devoted to the study of genetics, screening and primary prevention of gastrointestinal tumors. The major focus is on hereditary colorectal cancer syndromes, notably hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP), and pancreatic cancer. She runs several large family registries of patients and families at high risk of cancer, where detailed medical histories and DNA samples are collected for research purposes. These registries form the nidus of several projects aimed at gene-finding, evaluation of genotype-phenotype relationships in mutation carriers, as well as the clinical impact of genetic testing on patients and their families.Dr. Syngal also directs several studies aimed at early cancer detection (particularly at discovery and validation of serum biomarkers for colorectal and esophageal cancer) and is a funded investigator of the NCI-supported Early Detection Research Network.
Finally, her group is involved in several studies evaluating novel approaches to cancer screening, including fecal DNA tests, chromoendoscopy, and imaging.




